达英-35联合二甲双胍治疗肥胖型多囊卵巢综合征的疗效观察

Efficacy of Diane-35 combined with metformin in the treatment of obese polycystic ovary syndrome

目的分析针对肥胖型多囊卵巢综合征患者采用达英・35联合二甲双胍治疗的临床效果及对性激素水平的影响。方法选取150例明确诊断为肥胖型多囊卵巢综合征患者,根据双色球法将其随机分成研究组(采用达英-35联合二甲双胍治疗)与对照组(采用达英-35治疗),每组75例。比较两组治疗前后体质量指数(BMI)、胰岛素指标、血糖及激素水平及临床疗效。结果治疗前,两组BMI、空腹胰岛素、性激素结合球蛋白及空腹血糖指标比较,差异无统计学意义(P>0.05);治疗后,研究组BMI、空腹胰岛素及空腹血糖指标较对照组显著降低,性激素结合球蛋白水平显著高于对照组,组间和组内比较差异具有统计学意义(P<0.05)。与治疗前比较,治疗后两组患者血清促黄体生成素(LH)、卵泡刺激素(FSH)及雌二醇(E_(2))水平均显著降低,且研究组血清LH、E_(2)、FSH水平均显著低于对照组,差异具有统计学意义(P<0.05)。研究组患者临床总有效率显著高于对照组(97.33%VS 88.00%),差异具有统计学意义(P<0.05)。结论针对肥胖型多囊卵巢综合征患者采用达英-35联合二甲双胍治疗的临床效果显著,值得临床推广与应用。

Objective To analyze the clinical effect of Diane-35 combined with metformin in the treatment of obese patients with polycystic ovary syndrome and its influence on hormone levels.Methods 150 patients with obese polycystic ovary syndrome were selected and randomly divided into the study group(treated with Diane-35 combined with metformin)and the control group(treated with Diane-35)according to the bicolor method,with 75 cases in each group.The body mass index(BMI),insulin index,blood glucose and hormone levels and clinical efficacy were compared between the two groups before and after treatment.Results Before treatment,there were no significant differences in BMI,fasting insulin,sex hormone-binding globulin and fasting blood glucose between the two groups(P>0.05).After treatment,BMI,fasting insulin and fasting blood glucose in the study group were significantly lower than those in the control group,and the levels of sex hormone binding globulin were significantly higher than those in the control group,and the differences between and within groups were statistically significant(P<0.05).Compared with before treatment,the levels of serum luteinizing hormone(LH),follicle-stimulating hormone(FSH)and estradiol(E_(2))in the two groups were significantly decreased after treatment,and the levels of serum LH,E_(2) and FSH in the study group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).The total clinical effective rate of the study group was significantly higher than that of the control group(97.33%VS 88.00%),and the difference was statistically significant(P<0.05).Conclusion The clinical effect of Diane-35 combined with metformin in the treatment of obese patients with polycystic ovary syndrome is significant,which is worthy of clinical promotion and application.